All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

An introduction to MPN: biology and treatment options

Jan 20, 2020
Share:

The MPN Hub were pleased to speak to Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT, during the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Tiziano Barbui provides an introduction to myeloproliferative neoplasms in relation to biology and treatment options.

Tiziano Barbui gives an in-depth overview of the biology and treatment landscape of myeloproliferative neoplasms (MPN). He discusses the types of neoplasms that constitute MPN and the identified phenotype that drives this disease. Additionally, he discusses the disease characteristics, risk factors and its evolutionary potential to cancer. Tiziano Barbui also talks about the current treatment guidelines in both the US and Europe such as the IPSET-thrombosis classification.

An introduction to MPN: biology and treatment options